Open Clinical Trials for Patients With Prostate Cancer

Not Yet Recruiting

biraterone, Enzalutamide, or Apalutamide in Castrate-Sensitive Prostate Cancer

The investigators have used national Veterans Health Administration (VHA) data to demonstrate real-world efficacy of abiraterone and enzalutamide in veterans with metastatic castration-resistant prostate cancer. In the real world that is the VHA, the investigators have successfully estimated g values that accurately predict overall survival, and the use of this metric in other settings should now be explored. In the egalitarian system that is the VHA, the treatment of prostate cancer is excellent, uniform across the US and indifferent to race. The choices made are clearly personalized, given not all men received all therapies, and younger veterans were treated more aggressively.

ID: NCT05422911

Sponsor: James J. Peters VAMC

Location: James J. Peters VAMC

18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate Cancer (PROSPYL)

The main purpose of this phase II trial study is to determine whether a positron emission tomography (PET)/computed tomography (CT) scan using 18F-DCFPyL affects the clinical management plan in veterans. In this study, the management plan prior to and after 18F-DCFPyL PET/CT will be recorded by specific questionnaires, and corresponding changes in management will be analyzed. The scan will be used to see how the disease has spread. Both the treatment strategies and probable disease outcomes as relevant to clinical endpoints will be assessed. This study is open to veterans only.

ID: NCT04390880

Sponsor, Investigator: VA Greater Los Angeles Healthcare System; Gholam Berenji, MD

Location: VA Greater Los Angeles Healthcare System

18F-DCFPyL PET-CT Scan and Prostate Cancer

The primary objective of this study is to assess the efficacy of 18F-DCFPyL PET-CT for initial staging of prostate cancer in veterans compared to conventional imaging (99mTc-MDP bone scan and diagnostic CT or MRI). The primary clinical endpoint of our study is the percentage of veterans with prostate cancer in which the 18F-DCFPyL PET-CT identifies M1 disease at initial staging. Secondary objectives included frequency of the change in primary treatment plan after initial staging.

ID: NCT03852654

Sponsor, Investigator: Lida Jafari, MD

Location: VA Greater Los Angeles Healthcare System